How big is Adverum Biotechnologies, Inc.?

As of Jun 18, Adverum Biotechnologies, Inc. has a market capitalization of 48.47 million, with net sales of 1.00 million and a net profit of -133.56 million over the last four quarters. The company reported shareholder's funds of 70.71 million and total assets of 179.84 million as of Dec 24.

Market Cap: As of Jun 18, Adverum Biotechnologies, Inc. has a market capitalization of 48.47 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Adverum Biotechnologies, Inc. reported net sales of 1.00 million and a net profit of -133.56 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 70.71 million and total assets of 179.84 million.

What does Adverum Biotechnologies, Inc. do?

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company focused on treating serious ocular and rare diseases. It has a market cap of $48.47 million and reported a net profit loss of $47 million as of March 2025.

Overview:<BR>Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -47 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 48.47 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -2.87<BR>Return on Equity: -505.49%<BR>Price to Book: 1.83<BR><BR>Contact Details:<BR>Address: 800 Saginaw Drive, REDWOOD CITY CA: 94063<BR>Tel: 1 650 2726269<BR>Fax: 1 650 3298151<BR>Website: https://adverum.com/

Who are in the management team of Adverum Biotechnologies, Inc.?

As of March 2022, the management team of Adverum Biotechnologies, Inc. includes Patrick Machado (Independent Chairman), Dr. Laurent Fischer (CEO), and several independent directors: Dr. Mehdi Gasmi, Dr. Eric Carter, Ms. Rekha Hemrajani, Dr. Mark Lupher, and Mr. James Scopa. This team provides governance and strategic direction for the company.

As of March 2022, the management team of Adverum Biotechnologies, Inc. includes the following individuals:<BR><BR>- Mr. Patrick Machado, Independent Chairman of the Board<BR>- Dr. Laurent Fischer, Chief Executive Officer and Director<BR>- Dr. Mehdi Gasmi, Director<BR>- Dr. Eric Carter, Independent Director<BR>- Ms. Rekha Hemrajani, Independent Director<BR>- Dr. Mark Lupher, Independent Director<BR>- Mr. James Scopa, Independent Director<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Should I buy, sell or hold Adverum Biotechnologies, Inc.?

Is Adverum Biotechnologies, Inc. overvalued or undervalued?

As of November 4, 2024, Adverum Biotechnologies, Inc. is considered a risky investment due to its overvaluation indicated by a high Price to Book Value of 2.24, low EV to EBIT of 0.11, negative EV to Sales ratio of -16.73, and significant stock declines of -36.83% year-to-date and -97.62% over five years, contrasting sharply with the S&P 500's performance.

As of 4 November 2024, the valuation grade for Adverum Biotechnologies, Inc. has moved from does not qualify to risky, indicating a deterioration in its investment appeal. The company appears to be overvalued, given its high Price to Book Value of 2.24, an extremely low EV to EBIT of 0.11, and a negative EV to Sales ratio of -16.73. Compared to peers, Adverum's EV to EBITDA ratio of 0.11 is significantly lower than XOMA Corp.'s -22.9484 and Alimera Sciences, Inc.'s 27.2619, highlighting its relative underperformance.<BR><BR>In terms of stock performance, Adverum has faced substantial declines, with a year-to-date return of -36.83%, compared to a positive 12.22% for the S&P 500, and a staggering -97.62% over the past five years against a 96.61% gain for the index. This stark contrast reinforces the notion that Adverum is currently overvalued in the market.

Is Adverum Biotechnologies, Inc. technically bullish or bearish?

As of September 5, 2025, Adverum Biotechnologies, Inc. is in a mildly bearish trend, with daily moving averages and weekly indicators supporting this outlook, despite some mildly bullish signals from the MACD; the stock has significantly underperformed the S&P 500, with a year-to-date return of -36.83% compared to the index's 12.22%.

As of 5 September 2025, the technical trend for Adverum Biotechnologies, Inc. has changed from sideways to mildly bearish. The current stance is bearish, driven by daily moving averages indicating a mildly bearish position, while weekly indicators such as the Dow Theory and OBV also reflect a mildly bearish outlook. Although the MACD shows mildly bullish signals on both weekly and monthly time frames, the overall sentiment is tempered by the bearish monthly Bollinger Bands and KST. <BR><BR>In terms of performance, the stock has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -36.83% versus the S&P 500's 12.22%, and a one-year return of -57.80% compared to 17.14% for the index.